NCT06381817
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients No drug interventions treatment 3 recruiting NCT06253637
Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program treatment 2 not_yet_recruiting NCT06316856
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia No drug interventions treatment 1 / 2 recruiting NCT05909527
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma No drug interventions treatment 1 / 2 active_not_recruiting NCT00199030
Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath treatment 2 completed NCT06633354
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL No drug interventions treatment 0 recruiting NCT02763384
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma treatment 2 terminated NCT05127135
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies No drug interventions treatment 1 unknown_status NCT00640796
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors treatment 1 completed NCT01186328
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) treatment 1 terminated NCT05038644
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia No drug interventions treatment 1 active_not_recruiting NCT00100152
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) treatment 1 terminated NCT06390319
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) treatment 2 not_yet_recruiting NCT05509855
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 No drug interventions Not Available Not Available enrolling_by_invitation NCT06514794
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy inT-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma treatment 2 not_yet_recruiting NCT04033302
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies No drug interventions treatment 1 / 2 unknown_status NCT05289687
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL treatment 2 recruiting NCT05376111
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients treatment 2 recruiting NCT03690011
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells No drug interventions treatment 1 recruiting NCT04984356
A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL treatment 1 / 2 completed NCT04972942
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma treatment 1 recruiting NCT02518113
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL treatment 1 / 2 completed NCT04860817
A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL No drug interventions treatment 0 withdrawn NCT01950286
Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden. No drug interventions Not Available Not Available completed NCT05832125
Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia No drug interventions Not Available Not Available recruiting NCT05596266
CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia No drug interventions treatment 1 recruiting NCT06561074
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) treatment 2 not_yet_recruiting NCT06316427
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma No drug interventions treatment 1 / 2 recruiting NCT06420076
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells No drug interventions treatment 1 / 2 recruiting NCT03081910
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen No drug interventions treatment 1 recruiting NCT05277753
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL No drug interventions treatment 1 recruiting NCT05995028
Universal 4SCAR7U Targeting CD7-positive Malignancies No drug interventions treatment 1 recruiting NCT05032599
Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia No drug interventions treatment 1 recruiting NCT04594135
Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies treatment 1 unknown_status NCT04934774
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances No drug interventions treatment 1 unknown_status NCT05679895
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL No drug interventions treatment 1 recruiting NCT05290155
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies No drug interventions treatment 1 recruiting NCT04480788
CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study No drug interventions treatment 1 unknown_status NCT05745181
Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma No drug interventions treatment 2 recruiting NCT04437420
Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90 No drug interventions Not Available Not Available unknown_status NCT06648889
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia No drug interventions treatment 2 not_yet_recruiting NCT06136364
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study No drug interventions treatment 1 recruiting NCT03422679
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies treatment 1 / 2 terminated NCT04785833
CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia No drug interventions treatment Not Available unknown_status NCT04318678
CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) treatment 1 active_not_recruiting NCT05398614
SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies No drug interventions treatment 1 unknown_status NCT01483690
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL treatment 1 / 2 terminated NCT06598722
BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma. No drug interventions treatment 2 recruiting NCT01363817
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma treatment 1 completed NCT05626400
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL No drug interventions treatment Not Available recruiting NCT05487495
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma No drug interventions treatment 1 unknown_status NCT04572308
Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells No drug interventions treatment 1 completed NCT04128501
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting treatment 2 recruiting NCT00408005
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma treatment 3 active_not_recruiting NCT05602194
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma supportive_care 3 recruiting NCT03519984
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia treatment 1 terminated NCT02538926
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma treatment 2 withdrawn NCT03504644
Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia treatment 1 / 2 recruiting NCT04582487
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL No drug interventions basic_science Not Available recruiting NCT03007147
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia treatment 3 active_not_recruiting NCT02767934
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia treatment 2 terminated NCT02484430
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia treatment 2 active_not_recruiting NCT00501826
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma treatment 2 recruiting NCT04620655
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL No drug interventions treatment Not Available unknown_status NCT06210750
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) treatment 2 withdrawn NCT05149378
Venetoclax Based Regimen for R/R T-ALL treatment 2 recruiting NCT04446130
Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients treatment 3 unknown_status NCT01769209
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia treatment 2 completed NCT01258998
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma No drug interventions treatment 2 completed NCT00873093
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma treatment 2 completed NCT01093586
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT02619630
Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old) treatment 2 recruiting NCT02228772
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults treatment 1 completed NCT00918333
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma treatment 1 / 2 completed NCT00061945
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia treatment 1 / 2 completed NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 1 completed NCT00052520
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation treatment 1 / 2 completed NCT02168140
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma treatment 1 completed NCT00301938
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes treatment 1 completed NCT00608361
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery treatment 1 completed NCT01567709
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma treatment 1 completed NCT01139970
Veliparib and Temozolomide in Treating Patients With Acute Leukemia treatment 1 active_not_recruiting NCT02112916
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma treatment 3 active_not_recruiting NCT00792948
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia treatment 2 active_not_recruiting